Show simple item record

AuthorThomas, Binny
AuthorPallivalapila, Abdulrouf
AuthorEl Kassem, Wessam
AuthorTarannum, Asma
AuthorAl Hail, Fatema
AuthorRijims, Mohammed
AuthorParappil, Hussain
AuthorBayo, Arabo Ibrahim
AuthorAhmad, Shamsa
AuthorNazar, Zachariah
AuthorStewart, Derek
AuthorAl Hail, Moza
Available date2020-08-10T07:35:02Z
Publication Date2020-07-18
Publication NameSystematic Reviews
Identifierhttp://dx.doi.org/10.1186/s13643-020-01418-2
CitationThomas, B., Pallivalapila, A., El Kassem, W. et al. Maternal and perinatal outcomes and pharmacological management of Covid-19 infection in pregnancy: a systematic review protocol. Syst Rev 9, 161 (2020). https://doi.org/10.1186/s13643-020-01418-2
URIhttp://hdl.handle.net/10576/15443
AbstractOver 4.2 million confirmed cases and more than 285,000 deaths, COVID-19 pandemic continues to harm significant number of people worldwide. Several studies have reported the impact of COVID-19 in general population; however, there is scarcity of information related to pharmacological management and maternal and perinatal outcomes during the pandemic. Altered physiological, anatomical, and immunological response during pregnancy makes it more susceptible to infections. Furthermore, during pregnancy, a woman undergoes multiple interactions with the health care system that increases her chance of getting infected; therefore, managing pregnant population presents a unique challenge. This systematic review seeks to answer the following questions in relation to COVID-19: What are the different clinical characteristics presented in maternal and perinatal population? What are the different maternal and perinatal outcome measures reported? What are the distinct therapeutic interventions reported to treat COVID-19? Is it safe to use "medications" used in the treatment of COVID-19 during antenatal, perinatal, postnatal, and breastfeeding? The search will follow a comprehensive, sequential three step search strategy. Several databases relevant to COVID-19 and its impact on pregnancy including Medline, CINAHL, and LitCovid will be searched from the inception of the disease until the completion of data collection. The quality of this search strategy will be assessed using Peer Review of Electronic Search Strategies Evidence-Based Checklist (PRESS EBC). An eligibility form will be developed for a transparent screening and inclusion/exclusion of studies. All studies will be sent to RefWorks, and abstraction will be independently performed by two researchers. Risk of bias will be assessed using Cochrane Risk of Bias tool for randomized controlled trials, Newcastle-Ottawa Quality Assessment Scale for non-randomized studies, and for case reports, Murad et al. tool will be used. Decision to conduct meta-analysis will be based on several factors including homogeneity and outcome measures reported; otherwise, a narrative synthesis will be deemed appropriate. This systematic review will summarize the existing data on effect of COVID-19 on maternal and perinatal population. Furthermore, to the best of our knowledge, this is the first systematic review addressing therapeutic management and safety of medicines to treat COVID-19 during pregnancy and breastfeeding. This systematic review has been registered and published with Prospero ( CRD42020172773 ).
Languageen
PublisherBMC
SubjectCOVID-19
Maternal
Perinatal
Pharmacological management
Pregnant
TitleMaternal and perinatal outcomes and pharmacological management of Covid-19 infection in pregnancy: a systematic review protocol
TypeArticle
Volume Number9
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record